- Home
- EXTR vs RCKT Comparison
EXTR vs RCKT Comparison
Compare EXTR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXTR | RCKT |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 340.9M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXTR | RCKT |
|---|---|---|
| Price | $16.93 | $3.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $21.80 | ★ $29.12 |
| AVG Volume (30 Days) | 1.2M | ★ 2.0M |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,181,108,000.00 | N/A |
| Revenue This Year | $12.45 | N/A |
| Revenue Next Year | $7.33 | N/A |
| P/E Ratio | $282.29 | ★ N/A |
| Revenue Growth | ★ 14.31 | N/A |
| 52 Week Low | $10.10 | $2.19 |
| 52 Week High | $22.89 | $13.35 |
Technical Indicators
Market Signals| Indicator | EXTR | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 56.13 |
| Support Level | $16.57 | $3.19 |
| Resistance Level | $17.29 | $3.57 |
| Average True Range (ATR) | 0.47 | 0.20 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 23.12 | 78.18 |
Price Performance
Historical ComparisonAbout EXTR Extreme Networks Inc.
Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.